Steven Pieper - Nov 10, 2021 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chief Financial Officer
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Stock symbol
XERS
Transactions as of
Nov 10, 2021
Transactions value $
$49,918
Form type
4
Date filed
11/12/2021, 04:06 PM
Previous filing
Oct 5, 2021
Next filing
Jan 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Purchase $49.9K +25K +15.81% $2.00 183K Nov 10, 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.97 to $2.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Remarks:

Chief Financial Officer